Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: multiple sclerosis (MS)

23-NEU-3991918 CQD hero_650x450

For Older Patients With Multiple Sclerosis, Discontinuing Disease-Modifying Therapy May Be an Option

Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy

Myelin

DELIVER-MS Trial Extended to Guide Philosophy for Long-Term Multiple Sclerosis Therapy

$1.1M award expands follow-up to six years with focus on clinical endpoints

brain MRI showing central vein sign in a patient with multiple sclerosis

The Case for Including the Central Vein Sign in the Next Diagnostic Criteria for Multiple Sclerosis

Biomarker promises a practical way to reduce misdiagnoses

23-NEU-3813859-drug-formulations-650×450
April 28, 2023/Neurosciences/Pediatrics

Switching Disease-Modifying Therapies in Pediatric Multiple Sclerosis: Insights From Real-World Data

Relapse rates were lower with oral or infusion therapy after initial injectable DMT

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

intravenous infusion line

Shorter Ocrelizumab Infusion Time for Multiple Sclerosis Does Not Affect Safety Profile

No notable difference in reactions with two-hour infusion in ENSEMBLE PLUS substudy

23-NEU-3642021-Generic-MS-Drugs-ADJ-650×450
March 16, 2023/Neurosciences/Podcast

Leveraging Real-World Evidence for Treating Multiple Sclerosis (Podcast)

Observational studies comparing disease-modifying therapies can help guide clinical decisions

23-NEU-3534432-CQD-Hero-1-650×450 (1)

It’s Time for a New Framework for Characterizing Multiple Sclerosis

A focus on biological processes should improve both research and management

22-NEU-3409067_central-vein-sign_650x450

Central Vein Sign on FLAIR* MRI Comparable to CSF Oligoclonal Bands for Diagnosing MS

Initial pilot study findings suggest a potential reduced need for cerebrospinal fluid testing

22-NEU-3087358_pediatric-multiple-sclerosis_650x450
September 27, 2022/Neurosciences/Pediatrics

Making Pediatrics More of a Priority in Multiple Sclerosis Treatment Trials

New review makes the case for earlier pediatric enrollment and other changes

22-NEU-3222062_mesenchymal-stem-cells_650x450

Phase 2 Trial Hints at Promise of Cellular Therapy for Progressive MS

Single-arm, open-label study offers proof of concept for MSC-NTF cells

BackPage 3 of 9Next

Advertisement

Ad